A Innovative Web-based Dance Movement Therapy

March 11, 2026 updated by: Chin-Tsung Shen

Developing and Evaluating the Effect of a Innovative Web-based Dance Movement Therapy on Alexithymia and Frailty in Women With Breast Cancer: An Experimental Study

The goal of this clinical trial is to develop an innovative web-based dance movement therapy (DMT) training platform and assess short-term outcomes before and after its implementation in women with breast cancer

Is the DMT training platform comprehensibility and acceptability among patients? Is the DMT training platform acceptability, usability, and feasibility among healthcare providers? Does the DMT training platform have effects on alexithymia and frailty among patients?

Researchers will compare experimental to a control (a a conventional care program) to see if DMT training platform works to treat severe asthma.

Participants will:

receive an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity .

complete training sessions three times per week, with each session lasting at least 70 min.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

67

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • National Yang Ming Chiao Tung University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who were about to start chemotherapy were recruited from a hospital in Taipei, Taiwan

Exclusion Criteria:

  • major illness (e.g., heart failure, stroke, blindness) or a pre-existing mental disorder
  • a history of limb amputation
  • prior participation in dance therapy before their breast cancer diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: The web-based DMT training intervention
Other: web-based dance movement therapy training intervention
Patients in the experimental group received an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity. Participants were encouraged to complete training sessions three times per week, with each session lasting at least 70 min. Each DMT training session was divided into four components: (1) Proprioception; (2)Warm-up and stretching techniques; (3) Main part; (4) Relaxation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Alexithymia
Time Frame: one year (2024/08/01-2025/07/31)
Alexithymia was assessed using the Chinese version of the Toronto Alexithymia Scale (TAS), a self-reported outcome measure [30-31]. The TAS consists of 20 items covering three key domains: difficulty in identifying and discriminating emotional cues, difficulty in verbally expressing emotions and feelings, and externally oriented thinking. Each item was rated on a 5-point Likert scale, ranging from 1 to 5, resulting in a total score range of 20 to 100, with higher scores indicating greater alexithymia.
one year (2024/08/01-2025/07/31)
Frailty
Time Frame: one year ( 2024/08/01-2025/07/31).
A breast cancer comprehensive frailty scale (BCCFS) was developed to assess frailty across three domains: deterioration in body function and mobility, negative emotional states, and cognitive impairment. The BCCFS comprises 16 items and has demonstrated strong psychometric properties, with a Cronbach's alpha of 0.91, indicating excellent internal consistency, and a test-retest reliability coefficient of 0.60 [32]. The validity and reliability of the BCCFS have been well established. Responses to each item were recorded on a five-point Likert scale, with higher scores indicating greater perceived frailty.
one year ( 2024/08/01-2025/07/31).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chin-Tsung Shen

Collaborators

Ministry of Science and Technology, Taiwan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2024

Primary Completion (Actual)

July 31, 2025

Study Completion (Actual)

October 31, 2025

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MacKay Medical University

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe